Sonoma Pharmaceuticals, Inc. (SNOA)
USD 1.8
(-10.89%)
USD 1.8
(-10.89%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 | 2.71 Million USD | -4.86% |
| 2023 | 2.85 Million USD | 7.32% |
| 2022 | 2.66 Million USD | 5.26% |
| 2021 | 2.53 Million USD | 15.42% |
| 2020 | 2.19 Million USD | -35.7% |
| 2019 | 3.4 Million USD | 18.99% |
| 2018 | 2.86 Million USD | 29.0% |
| 2017 | 2.22 Million USD | 35.43% |
| 2016 | 1.64 Million USD | 16.98% |
| 2015 | 1.4 Million USD | 28.86% |
| 2014 | 1.08 Million USD | 9.68% |
| 2013 | 992 Thousand USD | 4.09% |
| 2012 | 953 Thousand USD | 30.01% |
| 2011 | 733 Thousand USD | 29.73% |
| 2010 | 565 Thousand USD | 66.18% |
| 2009 | 340 Thousand USD | 31.27% |
| 2008 | 259 Thousand USD | -8.16% |
| 2007 | 282 Thousand USD | -11.04% |
| 2006 | 317 Thousand USD | -63.48% |
| 2005 | 868 Thousand USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 2.51 Million USD | -7.95% |
| 2024 Q3 | 2.95 Million USD | 17.59% |
| 2024 Q4 | 2.71 Million USD | -7.99% |
| 2024 FY | 2.71 Million USD | -4.86% |
| 2024 Q1 | 2.73 Million USD | -4.48% |
| 2023 FY | 2.85 Million USD | 7.32% |
| 2023 Q3 | 2.84 Million USD | -5.82% |
| 2023 Q2 | 3.02 Million USD | 8.5% |
| 2023 Q4 | 2.85 Million USD | 0.32% |
| 2023 Q1 | 2.78 Million USD | 4.69% |
| 2022 FY | 2.66 Million USD | 5.26% |
| 2022 Q4 | 2.66 Million USD | -7.5% |
| 2022 Q3 | 2.87 Million USD | 16.0% |
| 2022 Q2 | 2.48 Million USD | -5.27% |
| 2022 Q1 | 2.62 Million USD | 3.56% |
| 2021 Q3 | 2.95 Million USD | -20.14% |
| 2021 Q2 | 3.7 Million USD | -11.66% |
| 2021 FY | 2.53 Million USD | 15.42% |
| 2021 Q1 | 4.19 Million USD | 91.29% |
| 2021 Q4 | 2.53 Million USD | -14.47% |
| 2020 Q3 | 2.82 Million USD | -8.81% |
| 2020 FY | 2.19 Million USD | -35.7% |
| 2020 Q1 | 3.36 Million USD | -1.2% |
| 2020 Q4 | 2.19 Million USD | -22.41% |
| 2020 Q2 | 3.09 Million USD | -8.02% |
| 2019 Q3 | 3.21 Million USD | 8.87% |
| 2019 FY | 3.4 Million USD | 18.99% |
| 2019 Q1 | 2.6 Million USD | -9.25% |
| 2019 Q2 | 2.95 Million USD | 13.58% |
| 2019 Q4 | 3.4 Million USD | 6.03% |
| 2018 Q2 | 2.6 Million USD | 9.37% |
| 2018 FY | 2.86 Million USD | 29.0% |
| 2018 Q4 | 2.86 Million USD | 6.07% |
| 2018 Q3 | 2.7 Million USD | 3.76% |
| 2018 Q1 | 2.38 Million USD | 7.16% |
| 2017 FY | 2.22 Million USD | 35.43% |
| 2017 Q4 | 2.22 Million USD | 7.5% |
| 2017 Q3 | 2.06 Million USD | -0.91% |
| 2017 Q2 | 2.08 Million USD | 4.67% |
| 2017 Q1 | 1.99 Million USD | 21.46% |
| 2016 FY | 1.64 Million USD | 16.98% |
| 2016 Q2 | 1.67 Million USD | 13.92% |
| 2016 Q1 | 1.46 Million USD | 4.56% |
| 2016 Q3 | 1.61 Million USD | -3.41% |
| 2016 Q4 | 1.64 Million USD | 1.67% |
| 2015 Q3 | 1.35 Million USD | 9.39% |
| 2015 Q2 | 1.23 Million USD | -5.44% |
| 2015 Q1 | 1.3 Million USD | 20.04% |
| 2015 Q4 | 1.4 Million USD | 3.77% |
| 2015 FY | 1.4 Million USD | 28.86% |
| 2014 Q2 | 749 Thousand USD | -7.87% |
| 2014 Q4 | 1.08 Million USD | 12.16% |
| 2014 Q1 | 813 Thousand USD | -18.04% |
| 2014 Q3 | 970 Thousand USD | 29.51% |
| 2014 FY | 1.08 Million USD | 9.68% |
| 2013 Q1 | 818 Thousand USD | -14.17% |
| 2013 Q4 | 992 Thousand USD | 10.1% |
| 2013 Q3 | 901 Thousand USD | 2.85% |
| 2013 Q2 | 876 Thousand USD | 7.09% |
| 2013 FY | 992 Thousand USD | 4.09% |
| 2012 Q1 | 762 Thousand USD | 3.96% |
| 2012 FY | 953 Thousand USD | 30.01% |
| 2012 Q4 | 953 Thousand USD | -6.29% |
| 2012 Q3 | 1.01 Million USD | 14.66% |
| 2012 Q2 | 887 Thousand USD | 16.4% |
| 2011 FY | 733 Thousand USD | 29.73% |
| 2011 Q4 | 733 Thousand USD | 19.19% |
| 2011 Q3 | 615 Thousand USD | -5.09% |
| 2011 Q1 | 529 Thousand USD | -6.37% |
| 2011 Q2 | 648 Thousand USD | 22.5% |
| 2010 Q2 | 505 Thousand USD | 42.25% |
| 2010 Q4 | 565 Thousand USD | 0.36% |
| 2010 Q3 | 563 Thousand USD | 11.49% |
| 2010 FY | 565 Thousand USD | 66.18% |
| 2010 Q1 | 355 Thousand USD | 4.41% |
| 2009 Q2 | 265 Thousand USD | -5.36% |
| 2009 Q4 | 340 Thousand USD | 1.19% |
| 2009 FY | 340 Thousand USD | 31.27% |
| 2009 Q1 | 280 Thousand USD | 8.11% |
| 2009 Q3 | 336 Thousand USD | 26.79% |
| 2008 Q1 | 281 Thousand USD | -0.35% |
| 2008 Q2 | 290 Thousand USD | 3.2% |
| 2008 Q3 | 278 Thousand USD | -4.14% |
| 2008 Q4 | 259 Thousand USD | -6.83% |
| 2008 FY | 259 Thousand USD | -8.16% |
| 2007 FY | 282 Thousand USD | -11.04% |
| 2007 Q3 | 423 Thousand USD | 19.15% |
| 2007 Q2 | 355 Thousand USD | 0.0% |
| 2007 Q4 | 282 Thousand USD | -33.33% |
| 2006 Q4 | 317 Thousand USD | 0.0% |
| 2006 FY | 317 Thousand USD | -63.48% |
| 2005 Q4 | 868 Thousand USD | 0.0% |
| 2005 FY | 868 Thousand USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Cosmos Health Inc. | 4.78 Million USD | 43.225% |
| Safety Shot Inc | 1.86 Million USD | -45.429% |
| Bright Green Corporation | - USD | -Infinity% |
| Embecta Corp. | 152.1 Million USD | 98.212% |
| ANI Pharmaceuticals, Inc. | 111.19 Million USD | 97.555% |
| Aquestive Therapeutics, Inc. | 6.76 Million USD | 59.832% |
| Collegium Pharmaceutical, Inc. | 32.33 Million USD | 91.59% |
| Dynavax Technologies Corporation | 53.29 Million USD | 94.898% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | 95.857% |
| Intra-Cellular Therapies, Inc. | 11.64 Million USD | 76.655% |
| Pacira BioSciences, Inc. | 104.35 Million USD | 97.394% |
| PainReform Ltd. | - USD | -Infinity% |
| Sunshine Biopharma, Inc. | 5.73 Million USD | 52.587% |
| Sunshine Biopharma, Inc. | 5.73 Million USD | 52.587% |
| SCYNEXIS, Inc. | - USD | -Infinity% |
| China SXT Pharmaceuticals, Inc. | 809.75 Thousand USD | -235.78% |
| Journey Medical Corporation | 10.2 Million USD | 73.359% |
| Alpha Teknova, Inc. | 11.59 Million USD | 76.548% |
| Procaps Group, S.A. | 96.83 Million USD | 97.192% |
| Theratechnologies Inc. | 6.06 Million USD | 55.176% |
| Harrow Health, Inc. | 10.86 Million USD | 74.979% |
| Biofrontera Inc. | 10.9 Million USD | 75.073% |
| DURECT Corporation | 2.21 Million USD | -22.533% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 96.487% |
| Cronos Group Inc. | 30.33 Million USD | 91.038% |
| OptiNose, Inc. | 8.05 Million USD | 66.232% |
| Ironwood Pharmaceuticals, Inc. | 1.00 USD | -271899900.0% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 5.69 Million USD | 52.29% |
| Organogenesis Holdings Inc. | 28.25 Million USD | 90.376% |
| Guardion Health Sciences, Inc. | 2.67 Million USD | -1.565% |
| Cumberland Pharmaceuticals Inc. | 4.6 Million USD | 41.011% |
| Radius Health, Inc. | 278.64 Million USD | 99.024% |
| Universe Pharmaceuticals INC | 3.34 Million USD | 18.672% |
| ProPhase Labs, Inc. | 3.84 Million USD | 29.211% |
| Phibro Animal Health Corporation | 265.91 Million USD | 98.977% |
| Procaps Group S.A. | 96.83 Million USD | 97.192% |
| Alvotech | 74.43 Million USD | 96.347% |
| TherapeuticsMD, Inc. | - USD | -Infinity% |
| Viatris Inc. | 3.46 Billion USD | 99.922% |
| Rockwell Medical, Inc. | 5.87 Million USD | 53.688% |
| Aytu BioPharma, Inc. | 12.63 Million USD | 78.477% |
| SIGA Technologies, Inc. | 64.21 Million USD | 95.766% |
| Tilray Brands, Inc. | 252.08 Million USD | 98.921% |
| Lifecore Biomedical, Inc. | 39.97 Million USD | 93.199% |
| Shineco, Inc. | 1.58 Million USD | -71.165% |
| PetIQ, Inc. | 159.3 Million USD | 98.293% |
| Regencell Bioscience Holdings Limited | -152.77 Thousand USD | 1879.707% |
| Incannex Healthcare Limited | -10.01 Million USD | 127.149% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | 92.901% |
| Alimera Sciences, Inc. | 1.87 Million USD | -44.705% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 37.68 Million USD | 92.785% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Petros Pharmaceuticals, Inc. | 1.61 Million USD | -68.841% |
| Clever Leaves Holdings Inc. | 4.48 Million USD | 39.349% |
| Cyclo Therapeutics, Inc. | 254.35 Thousand USD | -968.991% |
| Avadel Pharmaceuticals plc | 10.38 Million USD | 73.805% |
| Hempacco Co., Inc. | 2.54 Million USD | -6.937% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 74.43 Million USD | 96.347% |
| Eagle Pharmaceuticals, Inc. | 47.79 Million USD | 94.311% |
| Lantheus Holdings, Inc. | 64.02 Million USD | 95.753% |
| Currenc Group, Inc. | 732.91 Thousand USD | -270.986% |
| Kamada Ltd. | 87.74 Million USD | 96.901% |
| Indivior PLC | 141.79 Million USD | 98.083% |
| Evoke Pharma, Inc. | 481.84 Thousand USD | -464.295% |
| Flora Growth Corp. | 8.5 Million USD | 68.042% |
| Cyclo Therapeutics, Inc. | 254.35 Thousand USD | -968.991% |
| Evolus, Inc. | 10.99 Million USD | 75.277% |
| HUTCHMED (China) Limited | 50.25 Million USD | 94.59% |
| Amphastar Pharmaceuticals, Inc. | 105.83 Million USD | 97.431% |
| Akanda Corp. | 1.28 Million USD | -111.284% |